DB:9U9

Stock Analysis Report

Executive Summary

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to extend human health span.


Snowflake Analysis

Excellent balance sheet and overvalued.

Share Price & News

How has Unity Biotechnology's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 9U9's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

12.0%

9U9

11.2%

DE Biotechs

7.3%

DE Market


1 Year Return

-28.1%

9U9

-5.1%

DE Biotechs

-17.7%

DE Market

Return vs Industry: 9U9 underperformed the German Biotechs industry which returned -5.1% over the past year.

Return vs Market: 9U9 underperformed the German Market which returned -17.7% over the past year.


Shareholder returns

9U9IndustryMarket
7 Day12.0%11.2%7.3%
30 Day-5.4%-5.3%-17.9%
90 Day-19.5%-21.9%-25.8%
1 Year-28.1%-28.1%-4.9%-5.1%-15.1%-17.7%
3 Yearn/a17.7%16.5%-18.7%-25.6%
5 Yearn/a-5.1%-7.5%-17.7%-29.0%

Price Volatility Vs. Market

How volatile is Unity Biotechnology's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Unity Biotechnology undervalued compared to its fair value and its price relative to the market?

2.25x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 9U9's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 9U9's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 9U9 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 9U9 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 9U9's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 9U9 is good value based on its PB Ratio (2.2x) compared to the DE Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Unity Biotechnology forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

58.0%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 9U9's forecast earnings growth is above the savings rate (-0.4%).

Earnings vs Market: Insufficient data to determine if 9U9's earnings are forecast to grow faster than the German market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 9U9's revenue is forecast to grow faster than the German market.

High Growth Revenue: Insufficient data to determine if 9U9's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 9U9 is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Unity Biotechnology performed over the past 5 years?

-7.6%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: 9U9 is currently unprofitable.

Growing Profit Margin: 9U9 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if 9U9's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare 9U9's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 9U9 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).


Return on Equity

High ROE: 9U9 has a negative Return on Equity (-68.08%), as it is currently unprofitable.


Next Steps

Financial Health

How is Unity Biotechnology's financial position?


Financial Position Analysis

Short Term Liabilities: 9U9's short term assets ($129.5M) exceed its short term liabilities ($17.2M).

Long Term Liabilities: 9U9's short term assets ($129.5M) exceed its long term liabilities ($13.3M).


Debt to Equity History and Analysis

Debt Level: 9U9 is debt free.

Reducing Debt: 9U9 has not had any debt for past 5 years.


Balance Sheet

Inventory Level: 9U9 has a low level of unsold assets or inventory.

Debt Coverage by Assets: 9U9's debt is not covered by short term assets (assets are -18498.1x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 9U9 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if 9U9 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Unity Biotechnology's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 9U9's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 9U9's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 9U9's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 9U9's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 9U9's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.2yrs

Average management tenure


CEO

Anirvan Ghosh

no data

Tenure

Dr. Anirvan Ghosh, Ph.D. serves as Chief Executive Officer of Unity Biotechnology, Inc. since March 20, 2020. Dr. Ghosh had been Senior Vice President of Research and Early Development at Biogen Inc. since ...


Leadership Team

NamePositionTenureCompensationOwnership
Nathaniel David
Co-Founder8.33yrsUS$2.86m4.98% $12.3m
Jamie Dananberg
Chief Medical Officer4.17yrsUS$951.85k0.90% $2.2m
Anirvan Ghosh
Chief Executive Officerno datano datano data
Jan van Deursen
9.17yrsno datano data
Judith Campisi
9.17yrsno datano data
Daohong Zhou
9.17yrsno datano data
Robert Goeltz
Chief Financial Officer2.5yrsUS$1.29m0.24% $587.7k
Douglas Rich
Senior Vice President of Operations2.92yrsno datano data
Daniel Marquess
Chief Scientific Officer4.25yrsno data0.71% $1.7m
Tamara Tompkins
General Counsel & Corporate Secretary2.75yrsno data0.044% $109.3k

4.2yrs

Average Tenure

50.5yo

Average Age

Experienced Management: 9U9's management team is considered experienced (4.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Nathaniel David
Co-Founder8.33yrsUS$2.86m4.98% $12.3m
Robert Taylor Nelsen
Independent Director8.33yrsno datano data
Camille Samuels
Independent Director5yrsUS$551.11k0.021% $52.7k
Paul Berns
Lead Independent Directorno dataUS$933.01k0.0069% $16.9k
Keith Leonard
Chairman4.17yrsUS$2.73m1.8% $4.4m
Kristina Burow
Independent Director8.33yrsUS$551.83k0.24% $586.0k
Graham Cooper
Independent Director2.92yrsUS$167.90k0.18% $439.5k
David Lacey
Independent Director2yrsUS$285.51kno data
Margo Roberts
Independent Director1.25yrsUS$533.51kno data

4.6yrs

Average Tenure

52yo

Average Age

Experienced Board: 9U9's board of directors are considered experienced (4.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 54.3%.


Top Shareholders

Company Information

Unity Biotechnology, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Unity Biotechnology, Inc.
  • Ticker: 9U9
  • Exchange: DB
  • Founded: 2009
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$273.776m
  • Listing Market Cap: US$246.918m
  • Shares outstanding: 47.61m
  • Website: https://www.unitybiotechnology.com

Number of Employees


Location

  • Unity Biotechnology, Inc.
  • 3280 Bayshore Boulevard
  • Suite 100
  • Brisbane
  • California
  • 94005
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
UBXNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDMay 2018
9U9DB (Deutsche Boerse AG)YesCommon StockDEEURMay 2018
0YC0LSE (London Stock Exchange)YesCommon StockGBUSDMay 2018

Biography

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to extend human health span. The company’s lead drug candidates include UBX0101 that is in Phase 1 clinical study for musculoskeletal disease; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was founded in 2009 and is headquartered in Brisbane, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/30 00:03
End of Day Share Price2020/03/27 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.